← All trials
NCT02336243
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2015
- Primary completion
- Mar 31, 2018
- Completion date
- Apr 30, 2018
- First posted
- Jan 12, 2015
- Last posted
- Nov 4, 2015
- Enrollment
- 2400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pontificia Universidad Catolica de ChileLead sponsor
- Pontificia Universidad Catolica de ChileOverall official - principal investigator
- Pontificia Universidad Catolica de ChileStudy director
- University of ChileCollaborator
- University of ChileStudy director
- University of ChileOfficial
- Pontificia Universidad Catolica de ChileOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.